Evidence map›Paper›PMID 42775908›Full record

ArticleEndocrine-related cancer2026

18F-CETO in adrenocortical carcinoma: first clinical-translational study of an adrenocortical-targeting PET tracer.

Adam Edholm, Liang Zhang, James MacFarlane, Tobias Åkerström, Russell Senanayake, Staffan Welin, Agnes Hegedus, Heok K Cheow, Ieva Lase, Peter Stålberg and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Adam EdholmDepartment of Medical Sciences, Uppsala University , Uppsala, Sweden.ORCID 0009-0000-5363-8313
Liang ZhangDepartment of Medical Sciences, Uppsala University , Uppsala, Sweden.ORCID 0000-0001-8448-6754
James MacFarlaneDepartment of Endocrinology, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK.
Tobias ÅkerströmDepartment of Surgical Sciences, Uppsala University , Uppsala, Sweden.
Russell SenanayakeDepartment of Endocrinology, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK.
Staffan WelinDepartment of Medical Sciences, Uppsala University , Uppsala, Sweden.
Agnes HegedusDepartment of Immunology, Genetics and Pathology, Uppsala University , Uppsala, Sweden.
Heok K CheowCambridge Endocrine Molecular Imaging Group, University of Cambridge , Cambridge, UK.
Ieva LaseDepartment of Medical Sciences, Uppsala University , Uppsala, Sweden.
Peter StålbergDepartment of Surgical Sciences, Uppsala University , Uppsala, Sweden.
Azita MonazzamDepartment of Medical Sciences, Uppsala University , Uppsala, Sweden.ORCID 0000-0002-5332-5816
Daniel GillettCambridge Endocrine Molecular Imaging Group, University of Cambridge , Cambridge, UK.
Luigi AlojCambridge Endocrine Molecular Imaging Group, University of Cambridge , Cambridge, UK.
Per HellmanDepartment of Surgical Sciences, Uppsala University , Uppsala, Sweden.
Hanna WargeliusDepartment of Medical Sciences, Uppsala University , Uppsala, Sweden.
John A TadrossDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK.
Gunnar AntoniDepartment of Medicinal Chemistry, Uppsala University , Uppsala, Sweden.
Franklin AigbirhioWolfson Brain Imaging Centre, University of Cambridge , Cambridge, UK.
Britt SkogseidDepartment of Medical Sciences, Uppsala University , Uppsala, Sweden.
Mark GurnellDepartment of Endocrinology, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK.
Samuel BackmanDepartment of Surgical Sciences, Uppsala University , Uppsala, Sweden.ORCID 0009-0002-5704-8817
Anders SundinDepartment of Surgical Sciences, Uppsala University , Uppsala, Sweden.
Ruth T CaseyDepartment of Endocrinology, Cambridge University Hospitals NHS Foundation Trust , Cambridge, UK.ORCID 0009-0006-9938-8819
Joakim CronaDepartment of Medical Sciences, Uppsala University , Uppsala, Sweden.ORCID 0000-0003-0677-4894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The adrenocortical-specific PET tracer [11C]metomidate (11C-MTO) shows high diagnostic accuracy in adrenocortical carcinoma (ACC), but complex radiochemistry and short half-life limit clinical implementation. The novel tracer para-chloro-2-[18F]fluoroethyletomidate (18F-CETO) may enable broader use. In this bicentric study, 20 ACC patients underwent PET/CT with 18F-CETO and [18F]fluoro-2-deoxy-D-glucose (18F-FDG), with 235 lesions identified. 18F-CETO detected more lesions than 18F-FDG at initial staging in 5/13 patients, whereas fewer lesions were detected at re-staging in 5/7 patients (P = 0.002). A further 70 patients with 18F-CETO or 11C-MTO-PET/CT and an anatomical imaging reference were used to explore the utility of adrenocortical imaging. Three adrenocortical imaging phenotypes were defined: homogeneous-high (n = 71), homogeneous-low (n = 11), and heterogeneous (n = 8), which showed differences in overall survival in exploratory analyses. Tumors were characterized by RNA sequencing and immunohistochemistry showing correlation between tracer-uptake to CYP11B1 expression and adrenocortical differentiation. These findings suggest a potential role for 18F-CETO in ACC phenotyping and initial staging.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaEtomidatePositron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedFemaleHumansMaleMiddle AgedEtomidateRadiopharmaceuticalsadrenocortical carcinomapositron-emission tomographytranslational

Identifiers

PMID42775908
PMCPMC13663316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.